![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | sus |
Metabolism | sus |
Excretion | sus |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII |
|
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H18N4 |
Molar mass | 350.425 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Sibopirdine, also known as EXP921, is a nootropic drug. [1]
Patent: [2]
4,5-Diazafluoren-9-one [50890-67-0] (1) is condensed with 4 molar equivalents of 4-picoline [108-89-4] (2) in the presence of 2 equivalents of acetic anhydride and acetic acid. The intermediate from this step may originally be a tertiary alcohol which then dehydrates under the reaction conditions to give [150896-71-2] (3). The olefin can then be reduced either by catalytic hydrogenation over 5% Pd/C or by sodium borohydride in alcohol to give [150896-72-3] (4). Alkylation with 4-picolyl chloride [10445-91-7] (5) in the presence of sodium hydroxide completed the synthesis of sibopirdine (6).